6/28/23, 12:41 AM ANDROMEDA-SHOCK Pathway Feedback Search Clinical Topics Home Studies ANDROMEDA SHOCK ANDROMEDA SHOCK Disease Sepsis and septic shock Trial question Is peripheral perfusion-guided resuscitation superior to lactate-guided resuscitation in patients with septic shock? Study design Multi-center Open label RCT Population Characteristics of study participants 53.0% female N = 424 47.0% male 424 patients (226 female, 198 male) Inclusion criteria: patients with septic shock Key exclusion criteria: bleeding, severe ARDS, do-not-resuscitate status, pregnancy Interventions N=212 peripheral perfusion-guided resuscitation N=212 lactate-guided resuscitation Primary outcome Death at 28 days 43.4 % 43.4 https://web.pathway.md/studies/recJUOM5MkhCQDWvH 1/2 6/28/23, 12:41 AM ANDROMEDA-SHOCK Pathway 3 34.9 32.5 % 21.7 % 10.8 % No significant difference 0.0 % Peripheral perfusion-guided resuscitation Lactate-guided resuscitation No significant difference in death at 28 days (34.9% vs. 43.4%; HR 0.75, 95% CI 0.55 to 1.02) Secondary outcomes Significant decrease in SOFA score at 72 hours (5.6 vs. 6.6; MD -1, 95% CI -1.97 to -0.02) Safety outcomes No significant difference in serious adverse events. Conclusion In patients with septic shock, peripheral perfusion-guided resuscitation was not superior to lactate- guided resuscitation with respect to death at 28 days. Reference Hernandez G, Ospina-Tascon GA, Damiani LP et al. Effect of a Resuscitation Strategy Targeting Peripheral Perfusion Status vs Serum Lactate Levels on 28-Day Mortality Among Patients With Septic Shock: The ANDROMEDA-SHOCK Randomized Clinical Trial. JAMA. 2019 Feb 19;321(7):654-664. Open reference URL https://web.pathway.md/studies/recJUOM5MkhCQDWvH 2/2